13F-HR: Sanofi Discloses Q2 2025 Equity Holdings in Latest 13F Filing
Institutional Holdings Report
Sanofi's latest 13F filing reveals its equity portfolio as of June 30, 2025, totaling over $175 million across ten distinct holdings.
Summary
- Sanofi, an institutional investment manager, filed a Form 13F-HR report.
- The report covers the calendar quarter ended June 30, 2025.
- The total market value of all equity securities reported is $175,742,794.
- The filing lists 10 distinct equity holdings.
- All reported holdings are managed with sole investment discretion.
- Key holdings include Inhibrx Biosciences, Inc. (valued at $16,523,604 with 1,157,926 shares), LAVA Therapeutics N.V. (valued at $2,533,681 with 1,919,455 shares), MeiraGTx Holdings plc (valued at $79,529,245 with 12,197,737 shares), Novavax (valued at $43,347,030 with 6,880,481 shares), AnaptysBio (valued at $18,246,557 with 821,917 shares), IGM Biosciences (valued at $1,611,652 with 1,438,975 shares), Eledon (valued at $2,208,596 with 814,980 shares), Inozyme, Inc (valued at $1,773,020 with 443,255 shares), Q32 Bio Inc. (valued at $363,684 with 244,083 shares), and Omada Health Inc. (valued at $9,605,725 with 524,903 shares).
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of equity holdings and does not contain qualitative information to assess sentiment beyond the mere existence of investments.
Future Outlook
NA
Industry Context
As a major pharmaceutical company, Sanofi's equity holdings in various biotechnology and healthcare firms reflect strategic investments within its broader industry, potentially indicating areas of interest or partnerships in the life sciences sector.
Stakeholder Impact
- Provides transparency to shareholders and the market regarding Sanofi's equity investment portfolio, offering insights into its investment strategy and exposure to specific companies.
Key Dates
| Date | Description |
|---|---|
| 06-30-2025 | End of the calendar quarter for which the report is filed. |
| 07-29-2025 | Date the report was signed and submitted by Alexandra Roger, Head of Legal Corporate & Finance for Sanofi. |
Keywords
Sanofi, 13F, Institutional Holdings, Equity Portfolio, Investment Management, Biotechnology Stocks, Pharmaceutical Investments, Healthcare Stocks, Q2 2025
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.